Rosuvastatin alcohol
Searched over 200M research papers for "rosuvastatin alcohol"
Summary
5 papers analyzed
These studies suggest that rosuvastatin can preserve angiogenesis after heavy drinking and has various therapeutic benefits, including reducing serum lipid levels, improving cardiac function, and resolving non-alcoholic steatohepatitis.
Not a yes or no question
To use the Consensus Meter, try asking a simple yes or no question
Research summarized with Copilot
Beta20 papers analyzed
The Interaction Between Rosuvastatin and Alcohol: Implications for Cardiovascular and Liver Health
Cardiovascular Health: Rosuvastatin and Alcohol Consumption
Effects of Alcohol on Angiogenesis Post-Myocardial Infarction
Moderate alcohol consumption has been associated with cardioprotective effects, but heavy drinking poses significant risks for cardiovascular health. A study investigated the impact of varying alcohol consumption levels on myocardial infarction in rats, focusing on angiogenesis and the role of rosuvastatin. Low-dose ethanol consumption (0.5 g/kg/day) promoted angiogenesis, evidenced by increased vascular endothelial growth factor (VEGF) and decreased endostatin levels. Conversely, high-dose ethanol (5 g/kg/day) inhibited angiogenesis, with unchanged VEGF and elevated endostatin levels. Notably, rosuvastatin treatment (10 mg/kg/day) in the context of high ethanol intake preserved angiogenesis by upregulating VEGF, suggesting that rosuvastatin can mitigate the negative effects of heavy drinking on heart health.
Rosuvastatin Dosage and Prognosis in Acute Myocardial Infarction with Atrial Fibrillation
In patients with acute myocardial infarction (AMI) and new-onset atrial fibrillation (AF), different dosages of rosuvastatin (10 mg and 20 mg) were evaluated for their impact on prognosis. Both dosages significantly reduced serum lipid levels and improved heart function over 12 months. Factors such as age, smoking, alcohol consumption, and diabetes were identified as independent risk factors for AF and ischemic events. Importantly, no significant difference in adverse clinical events was observed between the two dosages, indicating the safety and efficacy of higher rosuvastatin doses in improving cardiac outcomes in these patients.
Liver Health: Rosuvastatin and Non-Alcoholic Steatohepatitis
Rosuvastatin Monotherapy in Non-Alcoholic Steatohepatitis (NASH)
Rosuvastatin has shown promise in treating non-alcoholic steatohepatitis (NASH), a severe form of non-alcoholic fatty liver disease. In a study involving patients with NASH, metabolic syndrome, and dyslipidemia, rosuvastatin monotherapy (10 mg/day) over 12 months led to the complete resolution of NASH in 19 out of 20 patients. Significant improvements were observed in liver enzymes, fasting plasma glucose, and lipid profiles. These findings suggest that rosuvastatin not only ameliorates liver pathology but also reduces the risk of vascular and liver-related morbidity and mortality in NASH patients.
Conclusion
The interaction between rosuvastatin and alcohol consumption has significant implications for both cardiovascular and liver health. While moderate alcohol consumption may have some cardioprotective effects, heavy drinking is detrimental. Rosuvastatin can counteract the negative effects of heavy alcohol consumption on angiogenesis post-myocardial infarction and improve outcomes in AMI patients with AF. Additionally, rosuvastatin monotherapy shows potential in resolving NASH and improving metabolic parameters. These findings underscore the importance of considering both alcohol consumption and appropriate rosuvastatin dosing in managing cardiovascular and liver diseases.
Sources and full results
Most relevant research papers on this topic
